LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akciju saraksts・Cogent Biosciences Inc

Cogent Biosciences Inc

Slēgts

38.64 -1.78

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

38.42

Max

38.88

Galvenie mērījumi
By Trading Economics
Ienākumi	-22M -102M
EPS	-0.5
Darbinieki	258
EBITDA	-30M -109M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+34.31% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	408M 6B
Iepriekšējā atvēršanas cena	40.42
Iepriekšējā slēgšanas cena	38.64

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

4.88 / 5.87 Atbalsts un pretestība

Cogent Biosciences Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. marts 23:35 UTC

Galvenie ziņu notikumi

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

2026. g. 1. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

2026. g. 1. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

2026. g. 1. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

2026. g. 1. marts 23:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

2026. g. 1. marts 23:19 UTC

Galvenie ziņu notikumi

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

2026. g. 1. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

2026. g. 1. marts 23:14 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

2026. g. 1. marts 22:55 UTC

Galvenie ziņu notikumi

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

2026. g. 1. marts 22:54 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

2026. g. 1. marts 22:53 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

2026. g. 1. marts 22:38 UTC

Tirgus saruna

Galvenie ziņu notikumi

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

2026. g. 1. marts 22:21 UTC

Peļņas

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

2026. g. 1. marts 22:17 UTC

Tirgus saruna

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

2026. g. 1. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

2026. g. 1. marts 22:00 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

2026. g. 1. marts 21:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Spot Gold Up as Investors Shield Against Risk -- Market Talk

2026. g. 1. marts 21:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

2026. g. 1. marts 21:30 UTC

Tirgus saruna

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

2026. g. 1. marts 21:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

2026. g. 1. marts 21:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

2026. g. 1. marts 20:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

2026. g. 1. marts 20:40 UTC

Tirgus saruna

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

2026. g. 1. marts 20:24 UTC

Tirgus saruna

Galvenie ziņu notikumi

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Salīdzinājums

Cenas izmaiņa

Cogent Biosciences Inc Prognoze

Cenas mērķis

By TipRanks

34.31% augšup

Prognoze 12 mēnešiem

Vidējais 52.18 USD 34.31%

Augstākais 67 USD

Zemākais 35 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Cogent Biosciences Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.88 / 5.87Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.